Tagista, tablets 24 mg 30 pcs

Name: Tagista, tablets 24 mg 30 pcs
SKU: 238311
Availability: InStock

€3.75

EAN: 4607143560635 SKU: 238311 Categories: Dizziness remedies, Medicine, Neurology and Psychiatry

Description

Betahistine improves microcirculation of the labyrinth, it is used in pathology of the vestibular apparatus.

The drug acts mainly on histamine H1- and H3-receptors of the inner ear and vestibular nuclei of the CNS.

With direct agonist effect on histamine H1-receptors of inner ear vessels and indirectly through effect on histamine H3-receptors it improves microcirculation and capillary permeability

and normalizes endolymph pressure in labyrinth and cochlea. At the same time, betahistine increases blood flow in the basilar artery.

It has a pronounced central effect, being an inhibitor of histamine H3-receptor nuclei of the vestibular nerve. It normalizes conduction in the neurons of the vestibular nuclei at the level of the brainstem.

The clinical manifestation of the above properties is reduction of the frequency and intensity of dizziness, decrease of tinnitus, improvement of hearing in case of its reduction.

Indications

Syndromes including vertigo and headache, tinnitus, progressive hearing loss, nausea and vomiting;

Meniere’s disease or syndrome.

Active ingredient

Betahistine

Composition

1 tablet contains

The active ingredient:

Betahistine dihydrochloride 24.0 mg;

Associates:

Cellulose microcrystalline – 64.25 mg,

Povidone (collidone 25) – 27.0 mg

Potato starch – 60.0 mg,

p> Citric acid – 6.0 mg,

Colloidal silica (aerosil), – 9.0 mg,

Talc – /8.4 mg,

Magnesium stearate – /1.35 mg.

How to take, the dosage
How to take, the dosage
Tablets 24 mg: 1 tablet 2 times a day.
Improvement is usually noticed at the beginning of therapy, stable therapeutic effect occurs after 2 weeks of treatment and may increase over several months of treatment.
Treatment is prolonged. The duration of the treatment course is determined individually.

Interaction
Interaction
There are no known cases of interaction or incompatibility with other drugs.

Special Instructions
Special Instructions
Effect on the ability to drive and other mechanisms
Betahistine has no sedative effect and does not affect the ability to drive a car or engage in activities requiring rapid psychomotor reactions.

Synopsis
Synopsis
Tablets are almost white or white with a creamy tint, flat-cylindrical with a bevel and a rib.

Features
Features
Time to reach maximum concentration in blood plasma – 3 hours.
Almost completely eliminated by the kidneys as a metabolite (2-pyridylacetic acid) within 24 hours.
The elimination half-life is 3 – 4 hours.

Contraindications
Contraindications
high sensitivity to any of the ingredients of the drug:
age under 18 years (due to lack of data);
pregnancy and lactation (due to lack of data).
With caution
gastric or duodenal ulcer (including in anamnesis), pheochromocytoma, bronchial asthma. These patients should be regularly monitored during treatment.
.

Side effects
Side effects
Gastrointestinal disorders. occurrence of hypersensitivity reactions from the skin (rash, itching, urticaria), Quincke’s edema.

Overdose
Overdose
Symptoms:
nausea, vomiting, seizures.
Treatment:
gastric lavage, taking activated charcoal, symptomatic therapy.

Similarities
Similarities
Betaserk, Vestibo, Betahistine, Betahistine NW, Tagista, Vertran

Additional information
Weight 0.022 kg
Shelf life
3 years. Do not use after the expiration date stated on the package.
Conditions of storage
In a dry, light-protected place at a temperature not exceeding 25°C. Keep out of reach of children.
Manufacturer
Chemopharm LLC, Russia
Medication form
pills
Brand
Chemopharm LLC